



Revance Therapeutics
 Investor Relations Department
 7555 Gateway Boulevard
 Newark, CA 94560
 United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: RVNC	
Last Trade:	23.15
Trade Time:	4:00 PM ET Aug 18, 2017
Change:	-0.30 (-1.279%)
Day Range	23.10 - 23.70
52-Week Range	12.35 - 28.30
Volume	112,451


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 3, 2017 [Revance Releases Second Quarter 2017 Results](#)
- Aug 2, 2017 [Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics](#)
- Aug 1, 2017 [Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics](#)
- Jul 24, 2017 [Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017](#)
- Jun 15, 2017 [Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Feb 28, 2017 [Annual Report \(10-K\)](#)
- Mar 24, 2017 [Proxy Statement \(DEF 14A\)](#)
- Aug 4, 2017 [Quarterly Report \(10-Q\)](#)
- May 9, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 4, 2016 [Quarterly Report \(10-Q\)](#)